A Bayesian network meta ‐analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple‐negative breast cancer

In conclusion, our results indicated that the addition of bevacizumab to CT was beneficial for TNBC patients, and olaparib had a great effect in PFS and ORR, especially for those with BRCA mutations. When combined with CT, targeted a gents including iniparib, sorafenib, cetuximab, and ipatasertib may have better efficacies for treating TNBC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research